Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Long-Term Investments (2017 - 2025)

Anaptysbio's Long-Term Investments history spans 9 years, with the latest figure at $7.7 million for Q3 2025.

  • For Q3 2025, Long-Term Investments fell 72.42% year-over-year to $7.7 million; the TTM value through Sep 2025 reached $7.7 million, down 72.42%, while the annual FY2024 figure was $35.5 million, 31.24% up from the prior year.
  • Long-Term Investments reached $7.7 million in Q3 2025 per ANAB's latest filing, down from $28.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $147.5 million in Q3 2022 to a low of $5.5 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $54.1 million, with a median of $40.2 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: tumbled 85.95% in 2021, then soared 2270.26% in 2022.
  • A 5-year view of Long-Term Investments shows it stood at $67.1 million in 2021, then soared by 113.03% to $142.9 million in 2022, then tumbled by 81.09% to $27.0 million in 2023, then soared by 31.24% to $35.5 million in 2024, then plummeted by 78.3% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Long-Term Investments are $7.7 million (Q3 2025), $28.0 million (Q2 2025), and $43.0 million (Q1 2025).